AURKB and neoplasm: Anlotinib suppresses tumor cell proliferation via inhibition of platelet-derived growth factor receptors α/β (PDGFR α/β), c-Kit, ret, as well as Aurora-B, c-FMS, and discoidin domain receptor 1 (DDR1), which are a group of newly identified kinase targets involved in tumor progression [8].